Why is IHL.AX stock so active pre-market today?

IHL.AX stock is active because Incannex’s Nasdaq parent executed a 1-for-30 reverse split effective 26 Feb 2026. The split increased headline liquidity and prompted cross-list adjustments, driving unusually high volume and intraday volatility on ASX.

What are the major valuation metrics for Incannex (IHL.AX)?

Incannex reports market cap **A$14,255,927**, EPS **-1.30**, PE **-0.03**, PB **0.75**, and cash per share **A$0.0217**. These metrics reflect a clinical-stage company with R&D-heavy spending and current liquidity but negative earnings.

What is Meyka AI's forecast for IHL.AX stock?

Meyka AI's forecast model projects a 12-month base case of **A$0.070** versus today’s **A$0.041**, implying **+70.73%** upside. The model includes scenario ranges and is a projection, not a guarantee.

What are the main risks investors should watch for with IHL.AX?

Watch for clinical trial results, fundraising needs, regulatory changes and any delisting risks on US markets. Reverse splits change share count but do not eliminate operational or financing risk inherent to clinical-stage biotech.

AU Stocks

IHL.AX Incannex ASX pre-market 27 Feb 2026: Most active A$0.041, reverse split

ByDanny Kontos February 26, 2026February 26, 2026

IHL.AX stock is the most active name in pre-market ASX trading on 27 Feb 2026 after a Nasdaq-driven corporate action pushed volume sharply higher. Incannex Healthcare Limited (IHL.AX) trades at A$0.041, down -10.87% intraday, with 61,360,016 shares changing hands versus an average of 6,427,691. The sudden activity follows the company’s announced 1-for-30 reverse stock split at its Nasdaq-listed parent, a move that has driven volume spikes and short-term price volatility. We provide a focused pre-market read on drivers, valuation, technicals and a model-based forecast for investors tracking IHL.AX stock